Autologous-cancer-cryoablation-mediated nanovaccine augments systematic immunotherapy

Area of Science:

• Immunology
• Nanotechnology
• Oncology

Background:

• Autologous tumor-based cancer vaccines show promise for personalized immunotherapy.
• Cryoablation generates in situ antigens but suffers from poor immunogenicity and memory maintenance due to fragment dissipation.

Purpose of the Study:

• To develop a nanovaccine with functional grippers to enhance in situ antigen capture after cryoablation.
• To improve the immunogenicity and durability of cancer vaccines by combining cryoablation with a nanovaccine and immune adjuvant.

Main Methods:

• Maleimide-modified Pluronic F127-chitosan nanoparticles encapsulating Astragalus polysaccharide (AMNPs) were synthesized.
• AMNPs were designed to capture tumor antigens, target lymph nodes, escape lysosomes, and activate dendritic cells for cross-presentation.
• The nanovaccine's efficacy was evaluated in a bilateral Lewis lung cancer tumor model.

Main Results:

• AMNP-mediated cryoablation led to complete primary tumor regression (100% inhibition) and reduced recurrence.
• Significant inhibition of untreated abscopal tumor growth was observed (3.84-fold decrease vs. saline).
• Long-term survival rate was markedly improved, reaching 83.33% in the treated group.

Conclusions:

• The developed nanovaccine effectively overcomes the limitations of cryoablation-induced immunotherapy.
• Lymph-node-targeted in situ cancer-cryoablation nanovaccines offer a promising strategy for personalized immunotherapy against metastatic cancers.